ROIV Stock Recent News

Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative A global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to mosliciguat, a novel, once-daily, inhaled soluble guanylate cyclase (sGC) activator, currently being studied for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data Transcript Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants Samuel Slutsky - LifeSci Capital, LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Samantha Lynn Semenkow - Citigroup Inc. Exchange Research David Risinger - Leerink Partners LLC, Research Division Yaron Werber - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Douglas Tsao - H.C.

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.

Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevant. All of these Vants are progressing well in 2025. However, its main near-term catalyst is Brepocitinib's Phase 3 in dermatomyositis. This could become the first approved therapy for this condition.

Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (ROIV 3.58%). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before.

Commercial-stage biotech Roivant Sciences (ROIV -2.79%) started the trading week with an earnings release. In retrospect, that might not have been the wisest move.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Matthew Gline - CEO & Director Stephanie Lee Griffin - Vice President of Special Projects Conference Call Participants Corinne Johnson - Goldman Sachs Group, Inc., Research Division David Reed Risinger - Leerink Partners LLC, Research Division Douglas Dylan Tsao - H.C.

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23.

BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update.

BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update.